---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-02-14T14:18:04.535509'
end_time: '2026-02-14T14:22:46.465668'
duration_seconds: 281.93
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: PTPN22
  gene_symbol: PTPN22
  uniprot_accession: Q9Y2R2
  protein_description: 'RecName: Full=Tyrosine-protein phosphatase non-receptor type
    22; EC=3.1.3.48 {ECO:0000269|PubMed:21719704, ECO:0000269|PubMed:27043286}; AltName:
    Full=Hematopoietic cell protein-tyrosine phosphatase 70Z-PEP; AltName: Full=Lymphoid
    phosphatase; Short=LyP; AltName: Full=PEST-domain phosphatase; Short=PEP;'
  gene_info: Name=PTPN22; Synonyms=PTPN8;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the protein-tyrosine phosphatase family. Non-
  protein_domains: Prot-tyrosine_phosphatase-like. (IPR029021); PTN12/18/22. (IPR047170);
    PTN22_cat. (IPR047253); PTP_cat. (IPR000242); PTPN22. (IPR016276)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 22
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q9Y2R2
- **Protein Description:** RecName: Full=Tyrosine-protein phosphatase non-receptor type 22; EC=3.1.3.48 {ECO:0000269|PubMed:21719704, ECO:0000269|PubMed:27043286}; AltName: Full=Hematopoietic cell protein-tyrosine phosphatase 70Z-PEP; AltName: Full=Lymphoid phosphatase; Short=LyP; AltName: Full=PEST-domain phosphatase; Short=PEP;
- **Gene Information:** Name=PTPN22; Synonyms=PTPN8;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the protein-tyrosine phosphatase family. Non-
- **Key Domains:** Prot-tyrosine_phosphatase-like. (IPR029021); PTN12/18/22. (IPR047170); PTN22_cat. (IPR047253); PTP_cat. (IPR000242); PTPN22. (IPR016276)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "PTPN22" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'PTPN22' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **PTPN22** (gene ID: PTPN22, UniProt: Q9Y2R2) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q9Y2R2
- **Protein Description:** RecName: Full=Tyrosine-protein phosphatase non-receptor type 22; EC=3.1.3.48 {ECO:0000269|PubMed:21719704, ECO:0000269|PubMed:27043286}; AltName: Full=Hematopoietic cell protein-tyrosine phosphatase 70Z-PEP; AltName: Full=Lymphoid phosphatase; Short=LyP; AltName: Full=PEST-domain phosphatase; Short=PEP;
- **Gene Information:** Name=PTPN22; Synonyms=PTPN8;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the protein-tyrosine phosphatase family. Non-
- **Key Domains:** Prot-tyrosine_phosphatase-like. (IPR029021); PTN12/18/22. (IPR047170); PTN22_cat. (IPR047253); PTP_cat. (IPR000242); PTPN22. (IPR016276)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "PTPN22" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'PTPN22' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **PTPN22** (gene ID: PTPN22, UniProt: Q9Y2R2) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan status update: We verified identity, gathered 2023–2024 primary and review evidence, and synthesized findings into a structured research report with citations, URLs, and dates. Below is the final report.

Comprehensive research report: Human PTPN22 (UniProt Q9Y2R2)

Verification of identity and nomenclature
- Target matches: PTPN22 encodes a non-receptor protein tyrosine phosphatase known as LYP (human; PEP in mouse), predominantly expressed in hematopoietic cells, with an N-terminal classical PTP catalytic domain and a C-terminal regulatory region containing four proline-rich motifs (P1–P4). The P1 motif mediates binding to the SH3 domain of C-terminal Src kinase (CSK). These features align with UniProt Q9Y2R2 annotations and confirm Homo sapiens identity and family/domain assignment (PTP family; EC 3.1.3.48) (Jan 2023, Nature Reviews Drug Discovery; https://doi.org/10.1038/s41573-022-00618-w) (stanford2023targetingproteinphosphatases pages 15-16). A 2024 review similarly details PTPN22 structure, proline-rich motifs, cytoplasmic predominance in immune cells, and CSK interaction via P1 (Jul 2024, Molecular and Cellular Biology; https://doi.org/10.1080/10985549.2024.2378810) (brownlie2024regulationoft pages 1-2).

1) Key concepts and definitions: biochemical function, substrates, and cellular localization
- Enzymatic activity and reaction: PTPN22 is a classical protein tyrosine phosphatase that catalyzes the removal of phosphate from phosphotyrosine residues on protein substrates (EC 3.1.3.48), acting as a negative regulator of proximal antigen-receptor signaling in lymphocytes (Jan 2023, Nature Reviews Drug Discovery; https://doi.org/10.1038/s41573-022-00618-w) (stanford2023targetingproteinphosphatases pages 15-16).
- Substrates and proximal TCR targets: Substrate-trapping and functional studies implicate Src-family kinases (notably Lck), ZAP-70, the TCR ζ chain, and signaling adaptors (e.g., Vav) as PTPN22 targets that it dephosphorylates to dampen early TCR signaling (Jan 2023, Nature Reviews Drug Discovery; https://doi.org/10.1038/s41573-022-00618-w; Jul 2024, Molecular and Cellular Biology; https://doi.org/10.1080/10985549.2024.2378810) (stanford2023targetingproteinphosphatases pages 15-16, brownlie2024regulationoft pages 1-2). In 2024, additional adaptor substrates in T cells (SLP‑76, FYB, HS1, Vav, SKAP1/2) were identified as potential PTPN22 targets upon TCR engagement, consistent with its role in microcluster signaling (Sep 2024, Biological Research; https://doi.org/10.1186/s40659-024-00536-8) (brownlie2024regulationoft pages 1-2).
- Cellular localization and complexes: PTPN22 is predominantly cytosolic in hematopoietic cells but functions at the plasma membrane/immune synapse through recruitment to CSK- and PAG-associated complexes. The proline-rich P1 motif mediates PTPN22–CSK association; imaging and nanoscale studies indicate PTPN22 contributes to recruitment of CSK-containing nanoclusters at later synapse stages to restrain signaling and LFA‑1–dependent adhesion/migration (Jul 2024, Molecular and Cellular Biology; https://doi.org/10.1080/10985549.2024.2378810; Jan 2024, Cells; https://doi.org/10.3390/cells13030231) (brownlie2024regulationoft pages 1-2, salmond2024targetingproteintyrosine pages 5-7).

2) Recent developments and latest research (prioritized 2023–2024)
- Gene-editing mechanism in human T cells: CRISPR/Cas9 editing of primary human naive T cells showed that PTPN22 R620W (rs2476601) “risk” editing or complete PTPN22 KO increased activation following non-specific TCR engagement. In islet antigen-specific models, loss of PTPN22 function or expression of the 620W variant enhanced signaling and proliferation of lower-avidity self-reactive TCRs, supporting a mechanism of lowering activation thresholds and expanding mildly self-reactive clones (Mar 2023, eLife; https://doi.org/10.7554/eLife.81577) (anderson2023ptpn22r620wgene pages 1-2, anderson2023ptpn22r620wgene pages 19-20, anderson2023ptpn22r620wgene pages 21-21).
- Expanded substrate scope and microcluster regulation: 2024 work identified multiple adaptor proteins (SLP‑76, Vav, FYB, HS1, SKAP1/2) as potential PTPN22 substrates and demonstrated co-localization with SLP‑76 microclusters upon TCR engagement, refining our understanding of how PTPN22 modulates signalosome assembly and actin-coupled signaling (Sep 2024, Biological Research; https://doi.org/10.1186/s40659-024-00536-8) (brownlie2024regulationoft pages 1-2).
- Regulatory post-translational modifications and partners: PTPN22 is regulated by phosphorylation (e.g., Lck-dependent Y536; GSK3-dependent S325) and by interactions with partners such as CSK, Grb2, UBASH3A, EB1, PSTPIP1 and 14‑3‑3, which together tune localization, stability, and activity in T cells (Jul 2024, Molecular and Cellular Biology; https://doi.org/10.1080/10985549.2024.2378810) (brownlie2024regulationoft pages 1-2).
- Therapeutic targeting state-of-the-art: A 2023 drug discovery review and 2024 immunotherapy review highlight PTPN22 as an intracellular immune checkpoint with translational interest, but note limited in vivo-suitable inhibitors; LTV‑1 has been reported to reduce autoreactive B cells in tolerance models, and catalytic inactivation (C227S) phenocopies deletion, reinforcing catalytic dependence of immune effects (Jan 2023, Nature Reviews Drug Discovery; https://doi.org/10.1038/s41573-022-00618-w; Jan 2024, Cells; https://doi.org/10.3390/cells13030231) (stanford2023targetingproteinphosphatases pages 15-16, salmond2024targetingproteintyrosine pages 5-7).

3) Current applications and real-world implementations
- Functional gene editing for mechanistic dissection and potential cell therapies: The eLife 2023 study demonstrates precise donor-templated editing of PTPN22 in primary human T cells, enabling within-donor comparisons of risk/non-risk/KO alleles and providing a template for future engineered T-cell therapies that modulate activation thresholds (Mar 2023, eLife; https://doi.org/10.7554/eLife.81577) (anderson2023ptpn22r620wgene pages 1-2).
- Drug discovery strategies: Reviews catalog orthosteric and non-orthosteric approaches across PTPs, emphasize challenges for PTPN22 (limited structural data on regulatory regions; only catalytic domain structure known), and discuss early tool compounds and immuno-oncology applications where PTPN22 inhibition or modulation might enhance T‑cell responses. These inform ongoing medicinal chemistry and screening strategies even as clinically advanced, selective PTPN22 inhibitors remain to be realized (Jan 2023, Nature Reviews Drug Discovery; https://doi.org/10.1038/s41573-022-00618-w; Jan 2024, Cells; https://doi.org/10.3390/cells13030231) (stanford2023targetingproteinphosphatases pages 15-16, salmond2024targetingproteintyrosine pages 5-7).

4) Expert opinions and analysis from authoritative sources
- Intracellular immune checkpoint role: Consensus across recent reviews positions PTPN22 as a key intracellular negative regulator of TCR signaling whose genetic variation constitutes one of the strongest non-HLA autoimmunity risk factors, and whose modulation could be leveraged to enhance anti-tumor immunity or correct dysregulated autoimmunity (Jan 2023, Nature Reviews Drug Discovery; https://doi.org/10.1038/s41573-022-00618-w; Jan 2024, Cells; https://doi.org/10.3390/cells13030231; Jul 2024, Molecular and Cellular Biology; https://doi.org/10.1080/10985549.2024.2378810) (stanford2023targetingproteinphosphatases pages 15-16, salmond2024targetingproteintyrosine pages 5-7, brownlie2024regulationoft pages 1-2).
- Variant mechanism: Authoritative analyses converge that the R620W substitution disrupts SH3-mediated binding to CSK, perturbs membrane-proximal inhibitory complexes (e.g., CSK–PAG–PTPN22), and thereby lowers signaling thresholds; recent gene-editing in human T cells directly demonstrates risk-allele phenotypes on activation and self-reactive TCR responses (Mar 2023, eLife; https://doi.org/10.7554/eLife.81577; Jan 2023, Nature Reviews Drug Discovery; https://doi.org/10.1038/s41573-022-00618-w; Jul 2024, Molecular and Cellular Biology; https://doi.org/10.1080/10985549.2024.2378810) (anderson2023ptpn22r620wgene pages 1-2, stanford2023targetingproteinphosphatases pages 15-16, brownlie2024regulationoft pages 1-2).

5) Relevant statistics and data from recent studies
- Human primary T cells edited to PTPN22 risk variant or KO exhibit increased activation marker expression following non-specific TCR engagement, and, with lower-avidity self-reactive TCRs, show enhanced proliferation and Th1 skewing relative to non-risk edited controls, functionally quantifying the effect of R620W or loss of PTPN22 on T-cell responsiveness (Mar 2023, eLife; https://doi.org/10.7554/eLife.81577) (anderson2023ptpn22r620wgene pages 1-2).
- Animal genetic models demonstrate catalytic dependence: a phosphatase-dead C227S knock-in phenocopies PTPN22 deletion effects on tumor immunity, supporting that enzymatic activity drives in vivo immune phenotypes, with implications for inhibitor design and expected on-target pharmacology (Jan 2023, Nature Reviews Drug Discovery; https://doi.org/10.1038/s41573-022-00618-w) (stanford2023targetingproteinphosphatases pages 15-16).

Biological processes and pathways
- Proximal TCR signaling: By dephosphorylating activating tyrosines on Lck and ZAP-70, and components such as TCRζ and Vav, PTPN22 dampens early signal propagation, curbing LAT/SLP‑76 signalosome assembly, downstream MAPK and mTOR activation, and transcriptional programs promoting IL‑2 and effector differentiation (Jan 2023, Nature Reviews Drug Discovery; https://doi.org/10.1038/s41573-022-00618-w; Jul 2024, Molecular and Cellular Biology; https://doi.org/10.1080/10985549.2024.2378810) (stanford2023targetingproteinphosphatases pages 15-16, brownlie2024regulationoft pages 1-2).
- Adhesion and migration: PTPN22 constrains LFA‑1–dependent adhesion and T-cell motility; loss elevates integrin-mediated adhesion and facilitates prolonged synapse interactions that can favor activation, particularly to low-affinity ligands (Jan 2024, Cells; https://doi.org/10.3390/cells13030231; Jul 2024, Molecular and Cellular Biology; https://doi.org/10.1080/10985549.2024.2378810) (salmond2024targetingproteintyrosine pages 5-7, brownlie2024regulationoft pages 1-2).
- Regulatory networks and partners: CSK binding via P1 is central to PTPN22 localization and function at the membrane; additional partners (UBASH3A, Grb2, EB1, PSTPIP1) and phosphorylation events fine-tune stability, catalytic activity, and spatial targeting during synapse maturation (Jul 2024, Molecular and Cellular Biology; https://doi.org/10.1080/10985549.2024.2378810; Jan 2023, Nature Reviews Drug Discovery; https://doi.org/10.1038/s41573-022-00618-w) (brownlie2024regulationoft pages 1-2, stanford2023targetingproteinphosphatases pages 15-16).

Disease associations and variant biology
- Shared autoimmunity locus: The common missense variant rs2476601 (R620W) is a major non-HLA risk allele across rheumatoid arthritis, type 1 diabetes, systemic lupus erythematosus and other autoimmune diseases. Mechanistically, R620W disrupts CSK binding and impairs assembly of inhibitory complexes at the immune synapse, lowering activation thresholds; human T-cell editing confirms functional consequences for proliferation and Th1 skewing in low-avidity self-reactive TCRs (Jan 2023, Nature Reviews Drug Discovery; https://doi.org/10.1038/s41573-022-00618-w; Mar 2023, eLife; https://doi.org/10.7554/eLife.81577; Jul 2024, Molecular and Cellular Biology; https://doi.org/10.1080/10985549.2024.2378810) (stanford2023targetingproteinphosphatases pages 15-16, anderson2023ptpn22r620wgene pages 1-2, brownlie2024regulationoft pages 1-2).
- Contextual immune phenotypes: Mouse genetics indicate PTPN22 impacts Th17-mediated autoimmunity, EAE, anaphylaxis, colitis, and diabetes models, underscoring cell type– and context-dependent outcomes relevant to therapeutic directionality (Jan 2023, Nature Reviews Drug Discovery; https://doi.org/10.1038/s41573-022-00618-w) (stanford2023targetingproteinphosphatases pages 15-16).

Open questions, limitations, and outlook
- Structural gap: Only the catalytic domain is structurally resolved; limited structural knowledge of regulatory regions and allosteric sites complicates rational design of selective, drug-like PTPN22 modulators (Jan 2023, Nature Reviews Drug Discovery; https://doi.org/10.1038/s41573-022-00618-w) (stanford2023targetingproteinphosphatases pages 15-16).
- Therapeutic strategy: While preclinical data position PTPN22 as an intracellular checkpoint target, clinically validated selective inhibitors remain scarce; gene editing and adoptive cell therapy engineering provide alternative routes to modulate PTPN22 function in a controlled, cell-intrinsic manner (Jan 2024, Cells; https://doi.org/10.3390/cells13030231; Mar 2023, eLife; https://doi.org/10.7554/eLife.81577) (salmond2024targetingproteintyrosine pages 5-7, anderson2023ptpn22r620wgene pages 1-2).

Alignment with mandatory verification steps
- Gene symbol and identity: PTPN22 matches the UniProt Q9Y2R2 description (human LYP/PEP) and catalytic class; literature consistently refers to human PTPN22 as a hematopoietic non-receptor PTP with the domain architecture and proline-rich motifs stated (Jan 2023, Nature Reviews Drug Discovery; Jul 2024, Molecular and Cellular Biology) (stanford2023targetingproteinphosphatases pages 15-16, brownlie2024regulationoft pages 1-2).
- Organism: All functional descriptions and variant analyses cited here are anchored in human PTPN22 or directly translatable human primary T-cell studies; mouse data are used only to contextualize immune phenotypes (anderson2023ptpn22r620wgene pages 1-2, stanford2023targetingproteinphosphatases pages 15-16). If literature with “PTPN-22” in C. elegans is encountered, it is considered a distinct ortholog and used solely for evolutionary context, not as a substitute for human evidence (Aug 2024, PLOS Genetics; https://doi.org/10.1371/journal.pgen.1011219) (binti2024aconservedprotein pages 21-22).

References with URLs and publication dates
- Stanford SM, Bottini N. Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders. Nature Reviews Drug Discovery. Jan 2023. https://doi.org/10.1038/s41573-022-00618-w (stanford2023targetingproteinphosphatases pages 15-16).
- Brownlie RJ, Salmond RJ. Regulation of T cell signaling and immune responses by PTPN22. Molecular and Cellular Biology. Jul 2024. https://doi.org/10.1080/10985549.2024.2378810 (brownlie2024regulationoft pages 1-2).
- Salmond RJ. Targeting protein tyrosine phosphatases to improve cancer immunotherapies. Cells. Jan 2024. https://doi.org/10.3390/cells13030231 (salmond2024targetingproteintyrosine pages 5-7).
- Anderson W et al. PTPN22 R620W gene editing in T cells enhances low-avidity TCR responses. eLife. Mar 2023. https://doi.org/10.7554/eLife.81577 (anderson2023ptpn22r620wgene pages 1-2, anderson2023ptpn22r620wgene pages 19-20, anderson2023ptpn22r620wgene pages 21-21).
- Bai B et al. The tyrosine phosphatase activity of PTPN22 is involved in T cell development via the regulation of TCR expression. International Journal of Molecular Sciences. Sep 2023. https://doi.org/10.3390/ijms241914505 (bai2023thetyrosinephosphatase pages 1-2).
- Binti S et al. A conserved protein tyrosine phosphatase, PTPN-22, functions in diverse developmental processes in C. elegans. PLOS Genetics. Aug 2024. https://doi.org/10.1371/journal.pgen.1011219 (ortholog context only) (binti2024aconservedprotein pages 21-22).

Conclusion
Human PTPN22 (UniProt Q9Y2R2) is a cytosolic, hematopoietic-restricted tyrosine phosphatase whose catalytic activity and CSK-anchored localization at the immune synapse serve as a key intracellular brake on proximal TCR signaling. It directly dephosphorylates Lck, ZAP-70, TCRζ, and adaptors to elevate activation thresholds, limit integrin-dependent adhesion, and shape downstream MAPK/mTOR and cytokine programs. The autoimmune risk variant R620W (rs2476601) disrupts CSK binding and lowers thresholds for activation—recently confirmed by allele-specific gene editing in primary human T cells—clarifying a mechanism for increased activation of low-avidity self-reactive clones. Emerging applications include engineered modulation in adoptive T-cell therapies and ongoing discovery efforts for selective small-molecule modulators, though structural gaps in regulatory domains remain a core challenge (stanford2023targetingproteinphosphatases pages 15-16, salmond2024targetingproteintyrosine pages 5-7, brownlie2024regulationoft pages 1-2, anderson2023ptpn22r620wgene pages 1-2).

References

1. (stanford2023targetingproteinphosphatases pages 15-16): Stephanie M. Stanford and Nunzio Bottini. Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders. Nature Reviews. Drug Discovery, 22:273-294, Jan 2023. URL: https://doi.org/10.1038/s41573-022-00618-w, doi:10.1038/s41573-022-00618-w. This article has 117 citations.

2. (brownlie2024regulationoft pages 1-2): Rebecca J. Brownlie and Robert J. Salmond. Regulation of t cell signaling and immune responses by ptpn22. Molecular and Cellular Biology, 44:443-452, Jul 2024. URL: https://doi.org/10.1080/10985549.2024.2378810, doi:10.1080/10985549.2024.2378810. This article has 8 citations and is from a domain leading peer-reviewed journal.

3. (salmond2024targetingproteintyrosine pages 5-7): Robert J. Salmond. Targeting protein tyrosine phosphatases to improve cancer immunotherapies. Cells, 13:231, Jan 2024. URL: https://doi.org/10.3390/cells13030231, doi:10.3390/cells13030231. This article has 6 citations and is from a poor quality or predatory journal.

4. (anderson2023ptpn22r620wgene pages 1-2): Warren Anderson, Fariba Barahmand-pour-Whitman, Peter S Linsley, Karen Cerosaletti, Jane H Buckner, and David J Rawlings. Ptpn22 r620w gene editing in t cells enhances low-avidity tcr responses. eLife, Mar 2023. URL: https://doi.org/10.7554/elife.81577, doi:10.7554/elife.81577. This article has 27 citations and is from a domain leading peer-reviewed journal.

5. (anderson2023ptpn22r620wgene pages 19-20): Warren Anderson, Fariba Barahmand-pour-Whitman, Peter S Linsley, Karen Cerosaletti, Jane H Buckner, and David J Rawlings. Ptpn22 r620w gene editing in t cells enhances low-avidity tcr responses. eLife, Mar 2023. URL: https://doi.org/10.7554/elife.81577, doi:10.7554/elife.81577. This article has 27 citations and is from a domain leading peer-reviewed journal.

6. (anderson2023ptpn22r620wgene pages 21-21): Warren Anderson, Fariba Barahmand-pour-Whitman, Peter S Linsley, Karen Cerosaletti, Jane H Buckner, and David J Rawlings. Ptpn22 r620w gene editing in t cells enhances low-avidity tcr responses. eLife, Mar 2023. URL: https://doi.org/10.7554/elife.81577, doi:10.7554/elife.81577. This article has 27 citations and is from a domain leading peer-reviewed journal.

7. (binti2024aconservedprotein pages 21-22): Shaonil Binti, Adison G. Linder, Philip T. Edeen, and David S. Fay. A conserved protein tyrosine phosphatase, ptpn-22, functions in diverse developmental processes in c. elegans. PLOS Genetics, 20:e1011219, Aug 2024. URL: https://doi.org/10.1371/journal.pgen.1011219, doi:10.1371/journal.pgen.1011219. This article has 10 citations and is from a domain leading peer-reviewed journal.

8. (bai2023thetyrosinephosphatase pages 1-2): Bin Bai, Tong Li, Jiahui Zhao, Yanjiao Zhao, Xiaonan Zhang, Tao Wang, Na Zhang, Xipeng Wang, Xinlei Ba, Jialin Xu, Yang Yu, and Bing Wang. The tyrosine phosphatase activity of ptpn22 is involved in t cell development via the regulation of tcr expression. International Journal of Molecular Sciences, 24:14505, Sep 2023. URL: https://doi.org/10.3390/ijms241914505, doi:10.3390/ijms241914505. This article has 7 citations and is from a poor quality or predatory journal.

## Citations

1. stanford2023targetingproteinphosphatases pages 15-16
2. brownlie2024regulationoft pages 1-2
3. binti2024aconservedprotein pages 21-22
4. salmond2024targetingproteintyrosine pages 5-7
5. bai2023thetyrosinephosphatase pages 1-2
6. https://doi.org/10.1038/s41573-022-00618-w
7. https://doi.org/10.1080/10985549.2024.2378810
8. https://doi.org/10.1038/s41573-022-00618-w;
9. https://doi.org/10.1186/s40659-024-00536-8
10. https://doi.org/10.1080/10985549.2024.2378810;
11. https://doi.org/10.3390/cells13030231
12. https://doi.org/10.7554/eLife.81577
13. https://doi.org/10.3390/cells13030231;
14. https://doi.org/10.7554/eLife.81577;
15. https://doi.org/10.1371/journal.pgen.1011219
16. https://doi.org/10.3390/ijms241914505
17. https://doi.org/10.1038/s41573-022-00618-w,
18. https://doi.org/10.1080/10985549.2024.2378810,
19. https://doi.org/10.3390/cells13030231,
20. https://doi.org/10.7554/elife.81577,
21. https://doi.org/10.1371/journal.pgen.1011219,
22. https://doi.org/10.3390/ijms241914505,